| Literature DB >> 26229524 |
Paraskevi Farazi1, Lina Lander2, Pavlos Pavlou3, Katherine Watkins2, Lynne Le2, Amr Soliman2.
Abstract
BACKGROUND: Causal relationships have been previously established between smoking and various cancers. In Cyprus, 39 % of men and 14 % of women reported daily smoking in 2008. The objective of this study was to compare the incidence of tobacco-related cancers to all other cancers by district and rural-urban classification to understand the impact of tobacco in Cyprus.Entities:
Keywords: Cancer; Cyprus; Epidemiology; Geographic; Tobacco; Trend
Year: 2015 PMID: 26229524 PMCID: PMC4520070 DOI: 10.1186/s12971-015-0048-5
Source DB: PubMed Journal: Tob Induc Dis ISSN: 1617-9625 Impact factor: 2.600
Fig. 1Proportion of smokers in the general population by urban and rural areas of sub-districts
Comparison of characteristics between participants diagnosed with tobacco-related cancer compared to all other cancers
| Characteristics | Other cancers | Tobacco-related Cancers1 |
| ||
|---|---|---|---|---|---|
| N = 18,780 | % | N = 3,635 | % | ||
|
| |||||
| Mean Age (StD) | 62.4 (17.1) | 67.2 (12.4) | <0.0001 | ||
| Median Age | 65.0 | 68.0 | |||
| Range | 0-107 | 4-100 | |||
| IQR | 53-75 | 60-76 | |||
|
| |||||
| Male | 8526 | 45.4 | 2910 | 80.1 | <0.0001 |
| Female | 10254 | 54.6 | 725 | 19.9 | |
|
| |||||
| Ever smoker | 3719 | 19.8 | 1721 | 47.3 | <0.0001 |
| Never smoker | 5428 | 28.9 | 471 | 13.0 | |
| Unknown | 9633 | 51.3 | 1443 | 39.7 | |
|
| |||||
| Local | 7584 | 40.4 | 1630 | 44.8 | <0.0001 |
| Regional | 4472 | 23.8 | 596 | 16.4 | |
| Distant | 3219 | 17.1 | 669 | 18.4 | |
| Unstaged | 3505 | 18.7 | 740 | 20.4 | |
|
| |||||
| Urban | 13015 | 69.3 | 2476 | 68.1 | 0.1563 |
| Rural | 5765 | 30.7 | 1159 | 31.9 | |
Notes:
1Tobacco-related cancers include: lung, urinary bladder, oral, pharyngeal, head and neck, and laryngeal cancers
Age-adjusted rates (per 100,000 persons) of tobacco-related cancers by Sub-District
| District | Sub-District | All Tobacco-related Cancers | Lung | Head and Neck/Orala | Urinary/Bladder | ||||
|---|---|---|---|---|---|---|---|---|---|
| AAR | 95 % CI | AAR | 95 % CI | AAR | 95 % CI | AAR | 95 % CI | ||
| Lefkosia | 10 | 34.5 | 32.4-36.6 | 18.9 | 17.4-20.5 | 4.3 | 3.6-5.1 | 11.2 | 10-12.4 |
| 11 | 28.9 | 22.1-35.7 | 17.5 | 12.2-22.8 | 3.3 | 1.0-5.5 | 8.1 | 4.6-11.7 | |
| 12 | 25.5 | 20.9-30.2 | 13.2 | 9.9-16.6 | 6.2 | 3.8-8.6 | 6.1 | 3.8-8.4 | |
| 13 | 31.2 | 24.3-38.1 | 17.2 | 12.2-22.2 | 4.6 | 1.8-7.5 | 9.4 | 5.5-13.2 | |
| 14 | 28.4 | 21.3-35.5 | 14.1 | 9.3-18.8 | 7.4 | 3.0-11.8 | 6.9 | 3.6-10.2 | |
| Total | 33.1 | 31.3-34.8 | 18.4 | 17.1-19.7 | 4.5 | 3.9-5.2 | 10.1 | 9.2-11.1 | |
| Ammochostos | 31 | 32.2 | 27.3-37.2 | 16.3 | 12.8-19.9 | 7.2 | 4.8-9.6 | 8.7 | 6.1-11.2 |
| Larnaka | 40 | 30.0 | 26.7-33.3 | 15.0 | 12.6-17.3 | 4.9 | 3.5-6.2 | 10.1 | 8.2-12.1 |
| 41 | 41.9 | 35.7-48.1 | 23.8 | 19.2-28.5 | 6.4 | 3.9-8.8 | 11.7 | 8.4-14.9 | |
| 42 | 20.7 | 13.3-28.0 | 9.7 | 4.6-14.8 | RSb | RSb | 8.1 | 3.5-12.7 | |
| 43 | 31.6 | 21.5-41.6 | 21.9 | 13.2-30.7 | RSb | RSb | 7.1 | 2.9-11.3 | |
| Total | 32.3 | 29.7-35.0 | 17.3 | 15.3-19.2 | 4.9 | 3.8-6.0 | 10.2 | 8.7-11.6 | |
| Lemesos | 50 | 36.3 | 33.8-38.7 | 17.8 | 16.1-19.5 | 5.5 | 4.5-6.5 | 13.0 | 11.5-14.5 |
| 51 | 28.6 | 22.1-35.1 | 14.8 | 10.2-19.5 | 3.7 | 1.3-6.0 | 10.1 | 6.3-14.0 | |
| 52 | 32.6 | 25.6-39.7 | 13.7 | 9.2-18.2 | 8.3 | 4.7-12.0 | 10.6 | 6.7-14.5 | |
| 53 | 24.6 | 19.3-29.9 | 9.0 | 5.8-12.1 | 6.8 | 3.8-9.9 | 8.8 | 5.8-11.8 | |
| Total | 35.0 | 32.9-37.1 | 17.2 | 15.7-18.6 | 5.7 | 4.8-6.5 | 12.1 | 10.9-13.3 | |
| Pafos | 60 | 40.3 | 35.2-45.3 | 19.3 | 15.8-22.8 | 7.5 | 5.3-9.7 | 13.5 | 10.5-16.4 |
| 61 | 33.8 | 26.4-41.2 | 17.7 | 12.4-23.1 | 6.7 | 3.3-10.1 | 9.3 | 5.4-13.2 | |
| 62 | 30.6 | 18.1-43.0 | 8.0 | 2.5-13.5 | 12.1 | 1.5-22.7 | 10.5 | 4.0-17.0 | |
| 63 | 35.3 | 26.2-44.5 | 17.9 | 11.4-24.4 | RSb | RSb | 13.1 | 7.9-18.4 | |
| Total | 36.7 | 33.2-40.3 | 18.3 | 15.8-20.8 | 6.7 | 5.1-8.3 | 11.7 | 9.7-13.6 | |
aIncludes: Lip, tongue, mouth, salivary glands, tonsil, other oropharynx, nasopharynx, hypopharynx, pharynx unspecified, nose/sinuses, larynx
bRates were suppressed (RS) if less than 5 cases were reported in a sub-district
Fig. 2Age-adjusted cancer incidence rates (per 100,000 persons) by Sub-District for all tobacco-related cancers combined, lung cancer, head/neck/oral cancer, and urinary/bladder cancer
Age-adjusted rates (per 100,000 persons) for urban and rural residence for tobacco-related cancers
| Cancer location | Overall AAR | Urban AAR | Rural AAR | Rate Ratio Urban:Rural | ||||
|---|---|---|---|---|---|---|---|---|
| AAR | 95 % CI | AAR | 95 % CI | AAR | 95 % CI | RR | 95 % CI | |
| Tobacco-related: All | 33.9 | 32.8-35.0 | 35.4 | 34.0-36.8 | 31.4 | 29.6-33.2 | 1.1a | 1.1-1.2 |
| Males | 57.9 | 55.8-60.0 | 60.8 | 58.2-63.5 | 53.2 | 49.7-56.6 | 1.1a | 1.1-1.2 |
| Females | 13.0 | 12.0-13.9 | 13.6 | 12.4-14.8 | 11.9 | 10.3-13.4 | 1.1 | 1.0-1.9 |
| Lung | 17.8 | 17.0-18.6 | 18.6 | 17.6-19.6 | 16.5 | 15.2-17.8 | 1.1 | 1.0-1.2 |
| Males | 29.9 | 28.4-31.5 | 30.9 | 29.0-32.8 | 28.6 | 26.1-31.1 | 1.1 | 1.0-1.2 |
| Females | 7.3 | 6.5-8.0 | 8.0 | 7.1-9.0 | 5.8 | 4.7-6.8 | 1.4a | 1.1-1.7 |
| Head and Neck/Oralb | 5.3 | 4.8-5.7 | 5.1 | 4.5-5.6 | 5.8 | 5.0-6.6 | 0.9 | 0.7-1.1 |
| Males | 8.5 | 7.7-7.7 | 8.3 | 7.3-9.3 | 8.8 | 7.4-10.3 | 0.9 | 0.8-1.2 |
| Females | 2.4 | 2.0-2.8 | 2.2 | 1.7-2.7 | 2.9 | 2.1-3.8 | 0.7 | 0.5-1.1 |
| Urinary/Bladder | 10.8 | 10.2-10.2 | 11.8 | 11.0-12.6 | 9.1 | 8.1-10.0 | 1.3a | 1.1-1.5 |
| Males | 19.5 | 18.2-18.2 | 21.6 | 20.0-23.2 | 15.8 | 13.9-17.6 | 1.4a | 1.2-1.6 |
| Females | 3.3 | 2.9-2.9 | 3.4 | 2.8-4.0 | 3.2 | 2.4-3.9 | 1.1 | 0.8-1.5 |
aRate Ratio is statistically significant (p < .05)
bIncludes: Lip, tongue, mouth, salivary glands, tonsil, other oropharynx, nasopharynx, hypopharynx, pharynx unspecified, nose/sinuses, larynx
Smoking prevalence among males ages 65–69 years in 1990 and 2000 compared to cancer rates for adults ages 15+ (1998–2007)
| Country | Proportion of male daily smokers % (UI) | Lunga | Bladdera | |
|---|---|---|---|---|
| 1990 | 2000 | |||
|
|
|
|
|
|
| Sweden | 22 % (18-27 %) | 17 % (14-21 %) | 20.8 | 17.4 |
| Sloveniab | 19 % (9-32 %) | 16 % (9-26 %) | 57.7 | 16.7 |
| Finlandb | 15 % (11-20 %) | 13 % (11-16 %) | 35.8 | 13.9 |
| Maltab | 27 % (14-44 %) | 24 % (15-34 %) | 36.8 | 25.5 |
| Slovakia b | 11 % (5-20 %) | 6 % (3-10 %) | 58.7 | 15.4 |
| Denmarkc b | 29 % (25-34 %) | 34 % (30-39 %) | 45.6 | 26.4 |
| Netherlandsb | 27 % (24-31 %) | 17 % (14-21 %) | 52.0 | 14.2 |
| United Kingdomb | 25 % (22-29 %) | 20 % (18-22 %) | 42.9 | 21.1 |
| Germanyb | 28 % (23-34 %) | 18 % (15-22 %) | 58.9d | 19.0d |
| Italyb | 29 % (25-34 %) | 21 % (18-24 %) | 53.2 | 33.9 |
| Austriab | 24 % (17-31 %) | 22 % (16-28 %) | 44.2 | 22.5 |
| Franceb | 26 % (22-31 %) | 17 % (13-21 %) | 52.5 | 19.3 |
| Czech Republicb | 20 % (10-32 %) | 22 % (16-28 %) | 61.5 | 20.0 |
| Estoniacb | 32 % (18-49 %) | 36 % (23-50 %) | 60.8 | 16.0 |
| Spainb | 28 % (24-34 %) | 24 % (20-28 %) | 49.2 | 34.8 |
| Lithuaniacb | 26 % (14-43 %) | 36 % (20-52 %) | 61.3 | 16.4 |
| Latviacb | 37 % (22-56 %) | 44 % (29-58 %) | 62.0 | 15.4 |
UI Uncertainty intervals
aPer 100,000. Cancer rates for Cyprus are derived from the present study. Cancer rates from all other countries are from CI5 (1998–2007)
bThese countries had higher lung and/or bladder cancer rates than Cyprus
cThese countries had a higher smoking prevalence than Cyprus for 1990 and/or 2000
dOnly includes the German state of Saarland
Smoking prevalence among females ages 65–69 years in 1990 and 2000 compared to cancer rates for adults ages 15+ (1998–2007)
| Country | Proportion of female daily smokers % (UI) | Lunga | Bladdera | |
|---|---|---|---|---|
| 1990 | 2000 | |||
|
|
|
|
|
|
| Swedenbc | 18 % (12-23 %) | 15 % (12-19 %) | 15.9 | 5.0 |
| Sloveniabc | 8 % (3-17 %) | 7 % (3-13 %) | 14.2 | 3.8 |
| Finlandbc | 6 % (4-9 %) | 8 % (6-10 %) | 10.2 | 2.9 |
| Maltabc | 8 % (3-17 %) | 6 % (3-11 %) | 6.4 | 5.3 |
| Slovakiac | 5 % (2-11 %) | 5 % (2-9 %) | 9.4 | 3.5 |
| Denmarkbc | 33 % (28-39 %) | 30 % (25-34 %) | 33.4 | 7.7 |
| Netherlandsbc | 14 % (11-17 %) | 14 % (11-18 %) | 22.6 | 3.4 |
| United Kingdombc | 24 % (20-29 %) | 19 % (17-22 %) | 24.6 | 6.1 |
| Germanybc | 10 % (7-14 %) | 10 % (7-12 %) | 19.2d | 5.1d |
| Italybc | 12 % (9-15 %) | 10 % (8-11 %) | 12.7 | 6.2 |
| Austriabc | 9 % (6-14 %) | 12 % (8-17 %) | 15.4 | 5.7 |
| Francebc | 10 % (8-13 %) | 9 % (6-12 %) | 11.1 | 2.9 |
| Czech Republicbc | 14 % (6-26 %) | 12 % (8-18 %) | 14.9 | 5.3 |
| Estoniac | 4 % (2-10 %) | 5 % (2-11 %) | 8.8 | 2.9 |
| Spainc | 6 % (4-8 %) | 4 % (3-5 %) | 6.0 | 4.5 |
| Lithuania | 2 % (1-5 %) | 2 % (1-5 %) | 6.6 | 3.0 |
| Latviac | 5 % (2-11 %) | 6 % (3-12 %) | 7.7 | 2.7 |
UI Uncertainty intervals
aPer 100,000. Cancer rates for Cyprus are derived from the present study. Cancer rates from all other countries are from CI5 (1998–2007)
bThese countries had a higher smoking prevalence than Cyprus for 1990 and/or 2000
cThese countries had higher lung and/or bladder cancer rates than Cyprus
dOnly includes the German state of Saarland